South African Tuberculosis Vaccine Initiative (SATVI)

Name

South African Tuberculosis Vaccine Initiative (SATVI)

Legal name

South African Tuberculosis Vaccine Initiative (SATVI)

Website

https://satvi.uct.ac.za

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Tuberculosis Vaccine Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Tuberculosis & Mycobacterial Diseases (HLAKAGAH)

akta.pro secondary industries

Vaccine Clinical Development & Regulatory Affairs (HLAIAEAM), Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK), Disease-Specific Global Initiatives (HIV/TB/Malaria/NTDs) (HLAJAOAE)

Keywords

• TB vaccine research
• Clinical trials
• Epidemiological studies
• Immunology research
• Vaccinology training

Headquarters

HQ city

Cape Town

HQ country

South Africa

HQ region

Africa

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Research Grants and Funding: SATVI operates as an academic research organization funded through grants from international research funders including Wellcome Leap and other global health organizations. Revenue is generated through competitive research grant funding rather than commercial product sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

SATVI designs and conducts clinical trials of new tuberculosis vaccine candidates and performs epidemiological studies in TB-endemic communities in the Western Cape, South Africa. It also delivers postdoctoral and postgraduate training in TB immunology, vaccinology, and clinical trial methods, supported by integrated immunology and immunopathology laboratories.

Product overview

SATVI is a research-focused organization (not a product company) operating as a unit within the University of Cape Town's Faculty of Health Sciences. Its offerings consist of tuberculosis vaccine clinical trials research, epidemiological studies, postgraduate research training, immunopathology studies, and community engagement programs. The organization conducts Phase 1b/2a clinical trials of novel TB vaccine candidates and publishes scientific research to advance global TB vaccine development.

Differentiator

Problem solved

Functional benefit

Products and services

• TB vaccine clinical trials Design and conduct of clinical trials of new tuberculosis vaccine candidates in high-burden TB settings, delivered for global vaccine developers and sponsors.
• MTBVAC TB vaccine clinical trial (SATVI site) Clinical trial of the MTBVAC tuberculosis vaccine candidate conducted at SATVI's Western Cape trial site for the sponsoring developer.
• Titan Vaccine Research Project participation SATVI's contribution to the Wellcome Leap Titan Vaccine Research Project, supporting accelerated development of tuberculosis vaccine candidates.
• TB epidemiological studies Epidemiological studies of tuberculosis transmission and disease in TB-endemic communities in the Western Cape, South Africa.
• TB immunology and immunopathology research Immunology and immunopathology research examining TB immune responses, including lymph node sampling, supporting clinical trial endpoints and mechanistic understanding.
• Postgraduate training in vaccinology and immunology Postdoctoral and postgraduate training program in TB vaccinology, immunology, and clinical trial methods offered through the University of Cape Town.

Quantifiable outcome

• MTBVAC vaccine candidate demonstrated similar or stronger immune responses compared to BCG vaccine in adults with comparable safety profile
• +1 more outcomes

Segments1 record

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• United Nations / WHO (UNHLM on TB)coreStrategic or Co-development Partner · 22 September 2023Professor Mark Hatherill addressed the UN High-level Meeting on Tuberculosis advocating for increased investment in TB vaccine R&D. This engagement shapes global TB policy and funding priorities.
• IAVI (A-050 Study)coreStrategic or Co-development PartnerCollaboration on the IAVI A-050 study evaluating MTBVAC vaccine candidate. Research findings published in Lancet Global Health demonstrating vaccine safety and immunogenicity in adults compared to BCG.
• UCT Lung InstitutecoreStrategic or Co-development PartnerJoint hosting of African parliamentarian delegations and global health representatives for TB research site visits. Co-location of operations at UCT Faculty of Health Sciences campus.
• African Parliamentarians and Global Health RepresentativesminorStrategic or Co-development PartnerDelegation of African parliamentarians visited SATVI on 15 May 2026 to witness cutting-edge TB research, building regional capacity and awareness for TB vaccine development.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Max Planck Institute for Infection Biology: Research institute with deep TB immunology and vaccine development programs, including MTBVAC co-development history. Comparable in advanced TB vaccine science and translational research focus.
• TuBerculosis Vaccine Initiative (TBVI): European-based TB vaccine research and development coordination body. Funds and coordinates TB vaccine candidates through discovery, preclinical, and clinical stages, overlapping directly with SATVI's translational research focus.
• National Institute for Research in Tuberculosis (NIRT): Indian Council of Medical Research institute focused on TB clinical trials, immunology, and epidemiology. Runs Phase 1-3 TB vaccine trials in a high-burden country setting analogous to SATVI's role in South Africa.
• IAVI: International AIDS Vaccine Initiative has expanded into TB vaccine development and is SATVI's direct co-development partner on the MTBVAC A-050 study. Operates a similar clinical trials model for infectious disease vaccines in low- and middle-income countries.
• Aeras (now part of IAVI): Former standalone TB vaccine product development partnership, now merged with IAVI. Historically ran TB vaccine clinical trials across multiple high-burden African and Asian sites, directly comparable to SATVI's clinical operations model.
• TuBerculosis Research Centre (ICMR-TRC), Chennai: India's premier TB research institution conducting clinical trials and epidemiological studies for TB vaccines and diagnostics. Comparable in mission (TB clinical research in a high-burden country) and academic institutional setting.

Emerging players

• Texas Biomedical Research Institute: Independent biomedical research institute with significant TB and infectious disease vaccine research programs including BSL-3 capabilities. Comparable in academic translational research model for infectious disease vaccines.
• Harvard Medical School Center for Global Health Delivery: Academic research center conducting TB epidemiology and vaccine-related research with global field sites. Comparable in academic research model and TB focus, though broader in scope than SATVI's vaccine specialization.
• London School of Hygiene & Tropical Medicine TB Centre: Leading UK academic center with active TB vaccine epidemiology and clinical research programs in Africa and Asia. Comparable academic translational research model and TB vaccine pipeline involvement.

Regional players

• Wellcome Centre for Infectious Disease Research in Africa (CIDRI-Africa): Wellcome-funded infectious disease research center based at the University of Cape Town, with overlapping institutional affiliation with SATVI. Comparable in Africa-based clinical research operations and Wellcome grant model, though broader in pathogen scope.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/user/SATVIUCT
• Facebookfacebook.com/SATVIUCT
• LinkedInlinkedin.com/company/south-african-tuberculosis-vaccine-initiative-satvi-

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about South African Tuberculosis Vaccine Initiative (SATVI)